Daily Sepsis Research Analysis
Analyzed 49 papers and selected 3 impactful papers.
Summary
Mechanistic and translational sepsis research advanced on three fronts: a JCI study identifies PLA2G5 as a circulating hemolytic driver and prognostic biomarker; a Nature Communications paper shows a Muribaculaceae-enriched microbiota primes TLR4-dependent hyperinflammation; and an npj Antimicrobials and Resistance study demonstrates a dual-action antimicrobial peptide adjuvant that boosts antibiotic efficacy and survival in murine sepsis.
Research Themes
- Hemolysis as a therapeutic target and biomarker in sepsis
- Microbiome-driven hyperinflammatory endotypes via TLR4 priming
- Host-directed antimicrobial peptide adjuvants restoring antibiotic efficacy
Selected Articles
1. Secreted phospholipase PLA2G5 acts as a hemolytic factor in sepsis.
PLA2G5 is induced in intestinal goblet cells during sepsis and circulates to trigger intravascular hemolysis via lipolytic activity on erythrocyte membranes. Genetic deletion or antibody neutralization protects mice from lethal sepsis, with improved iron homeostasis. In human sepsis (bacterial, fungal, viral), plasma PLA2G5 is elevated and predicts severity and mortality.
Impact: This study uncovers a previously unrecognized hemolytic pathway in sepsis and validates PLA2G5 as both a prognostic biomarker and a druggable target using genetic and antibody interventions.
Clinical Implications: Measuring plasma PLA2G5 could aid risk stratification. Therapeutic strategies targeting PLA2G5 or mitigating hemolysis (e.g., heme/hemoglobin scavengers) warrant investigation as adjuncts in severe sepsis.
Key Findings
- PLA2G5 is induced in colon cell types during sepsis and becomes a circulating factor.
- Pla2g5 knockout mice and mice treated with a PLA2G5-neutralizing antibody are protected from lethal sepsis.
- Circulating PLA2G5 causes intravascular hemolysis via lipolysis of erythrocyte membranes, impairing iron homeostasis.
- Human sepsis patients exhibit elevated plasma PLA2G5 levels that predict disease severity and mortality.
- Antibody treatment increases splenic red pulp macrophages and improves iron regulation.
Methodological Strengths
- Organism-wide spatial and transcriptional profiling identified tissue sources of PLA2G5.
- Convergent validation using genetic knockout and neutralizing antibody interventions plus human clinical correlations.
Limitations
- Predominantly murine models (endotoxemia and sepsis) may not capture full human heterogeneity.
- Interventional efficacy of PLA2G5 blockade has not been tested in clinical trials; human cohort sample sizes are not detailed.
Future Directions: Prospectively validate PLA2G5 as a biomarker; develop selective PLA2G5 inhibitors/antibodies; test combination strategies with heme scavengers in large-animal models and early-phase clinical trials.
Sepsis is a systemic response to infection with life-threatening consequences such as hemolysis, a predictor of mortality risks for the disease. Here, by measuring organism-wide changes in gene expression, we discovered that the secreted phospholipase PLA2G5 is induced in colon cell types during sepsis. The genetic deletion of Pla2g5 and treatment with a PLA2G5 antibody were both associated with protection from lethal sepsis. Treatment with a PLA2G5 antibody during sepsis was associated with increased splenic red pulp macrophages and im
2. A Muribaculaceae-enriched microbiota exacerbates TLR4-dependent Acinetobacter baumannii-induced hyperinflammatory sepsis.
A Muribaculaceae-dominant microbiota, driven by Sangeribacter muris KT1-3, primes macrophages and lowers the TLR4 activation threshold, producing lethal hyperinflammation in A. baumannii sepsis. The phenotype is transferable by FMT/co-housing and mediated by heat-stable <3 kDa metabolites; Tlr4−/− mice survive despite bacterial dissemination.
Impact: This work assigns causal, species-level microbiome drivers and specific metabolites to a hyperinflammatory sepsis endotype, reframing sepsis susceptibility as a microbiota-TLR4 axis phenomenon and opening preventive/modulatory avenues.
Clinical Implications: Microbiome profiling could identify patients at risk of hyperinflammatory sepsis and inform TLR4-modulating or microbiota-targeted interventions; translation requires human validation and metabolite identification.
Key Findings
- A Muribaculaceae-enriched microbiota dominated by Sangeribacter muris KT1-3 predisposes mice to fatal A. baumannii sepsis.
- The lethal hyperinflammatory phenotype transfers via fecal microbiota transplantation and co-housing.
- Fixed-dose LPS challenge elicits exaggerated TLR4-dependent cytokine responses independent of bacterial replication.
- Single-cell transcriptomics reveals a transcriptionally pre-activated macrophage state.
- KT1-3 releases heat-stable, <3 kDa metabolites that potentiate systemic cytokine surges.
- Tlr4-deficient mice with the susceptible microbiota survive despite persistent bacterial dissemination.
Methodological Strengths
- Causal inference via colonization, FMT, and co-housing across independently sourced mouse colonies.
- Integration of fixed-dose endotoxin challenges and single-cell transcriptomics to define immune priming.
Limitations
- Findings are limited to murine models; human validation and generalizability remain to be established.
- Specific metabolites were not chemically identified; mechanism of TLR4 threshold modulation requires elucidation.
Future Directions: Isolate and characterize KT1-3 metabolites; validate microbiota signatures and TLR4 priming in human cohorts; test microbiome or TLR4-targeted modulators in translational models.
Host survival during sepsis depends not only on pathogen burden but also on inflammatory thresholds calibrated by the gut microbiota. Here, we show that different survival outcomes were observed in genetically equivalent female C57BL/6 mouse populations depending on their specific gut microbiota configuration. A Muribaculaceae-enriched gut microbiota, characterized by the dominance of Sangeribacter muris KT1-3, predisposed mice to fatal sepsis caused by Acinetobacter baumannii via TLR4-dependent hyperinflammation. This lethal phenotype, reprodu
3. Antimicrobial peptide-induced inner membrane hyperpolarization is associated with antibiotic sensitization and attenuated MIC escalation in multidrug-resistant Gram-negative pathogens.
At sub-MIC levels, TP2-5 sensitized MDR Gram-negative bacteria to antibiotics and blunted MIC escalation during serial passage, associated with inner-membrane hyperpolarization and envelope perturbation. TP2-5 neutralized LPS and reduced TLR4-driven cytokines; in murine CLP sepsis, TP2-5 (± meropenem) achieved 100% survival with reduced bacterial burden and systemic cytokines.
Impact: Demonstrates a multifunctional peptide that both potentiates antibiotics and modulates host endotoxin responses, yielding survival benefits in a gold-standard sepsis model—highlighting a promising adjuvant strategy against MDR sepsis.
Clinical Implications: Supports development of peptide adjuvants to restore antibiotic efficacy and dampen endotoxemia in MDR sepsis; requires safety, pharmacokinetics, and efficacy testing in larger animals and early-phase trials.
Key Findings
- Sub-MIC TP2-5 increased antibiotic susceptibility of MDR E. coli in broth and 50% human serum.
- Combination with antibiotics attenuated MIC escalation over 21-day serial passage.
- Membrane potential assays and cryo-ET revealed inner-membrane hyperpolarization and envelope perturbation.
- TP2-5 neutralized LPS and reduced TLR4-dependent cytokine production.
- In murine CLP sepsis, TP2-5 alone or with meropenem achieved 100% survival with reduced bacterial burden and systemic cytokines.
Methodological Strengths
- Multi-modal mechanistic readouts (membrane potential assays, cryo-ET) with functional synergy testing under human serum conditions.
- Demonstration of survival benefit in a polymicrobial CLP sepsis model with reduced bacterial burden and cytokines.
Limitations
- Bacterial membrane potential was not measured in vivo; the causal role of hyperpolarization in protection remains to be established.
- Safety, pharmacokinetics, and resistance risks of TP2-5 are unknown; clinical translation requires further validation.
Future Directions: In vivo measurement of membrane potential, PK/tox studies, spectrum-of-activity and resistance profiling, and early-phase clinical development as an antibiotic adjuvant.
Antimicrobial resistance and dysregulated inflammation drive mortality in multidrug-resistant (MDR) sepsis. We evaluated the cationic peptide TP2-5 as a low-dose antibiotic adjuvant. At sub-MIC concentrations, TP2-5 enhanced antibiotic susceptibility of MDR E. coli in broth and 50% human serum, and in combination with antibiotics was associated with attenuated MIC escalation during 21-day serial passage. Membrane potential assays and cryo-electron tomography showed envelope perturbation characterized by inner-membrane hyperpolarization. This bi